Cite
HARVARD Citation
Farrah, T. et al. (2019). Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease. Hypertension. 74 (2), p. . [Online].